TBXUDirexion Daily Biotech Top 5 Bull 2X ETF
Seeks daily investment results of 200% of the daily performance of the Index.
By Direxion Funds · Launched 2025
Annual Cost
0.98%
#5,220 of 6,040 · expensive
Fund Size
$5M
#5,272 of 6,040 · small
Return (1Y)
N/A
Track Record
12 months
#4,715 of 6,040 · young
Performance
Total-return NAV · USDGrowth of $10,000
$15,120+51.2%
Total-return NAV, USD. Net of fund fees, before tax.
What's inside
How Beacon categorizes this fundAsset class
EquityRegion
North americaStrategy
Leveraged
Sector
Health careIndex tracked
NYSE Biotechnology Index
Holdings
By weightConcentration
synthetic exposure — holdings shown are derivatives collateral, not the fund's positions
DREYFUS GOVERNMENT CASH MANAGE
30.0%
GOLDMAN FINANCIAL
25.5%
ARGENX SE - ADR
10.1%
REGENERON PHARMACEUTICALS INC
8.6%
Amgen Inc.
8.5%
VERTEX PHARMACEUTICALS INC
8.2%
Gilead Sciences Inc.
8.1%
GOLDMAN SACHS LIQ ES FD A
5.4%
N/A
-1.5%
N/A
-4.7%
Asset allocation
Other
61.6%
Stocks
23.8%
Cash
14.7%
By sector
Healthcare
100.0%
Risk profile
Last 12 months · Sharpe & Sortino need 3+ yearsVolatility (1Y)
N/A
Max drawdown
-26.5%Moderate
Worst peak-to-trough loss
Sharpe (3Y)
Unavailable
Needs 3+ years of history
Sortino (3Y)
Not yet
Needs 3+ years of history
Listing
- Exchange
- NYSE Arca
Full fund details
- Objective
- Seeks daily investment results of 200% of the daily performance of the Index.
- Strategy
- Invests at least 80% of net assets in securities of the Index, aiming for 2X daily leveraged exposure to the top five U.S.-listed biotechnology companies. The Fund is non-diversified and rebalances daily to maintain its investment objective.
- Inception date
- September 30, 2025
- Fund family
- Direxion Funds
Similar funds
Same asset class, closest by strategy & exposureNext steps
Save TBXU to compare it with other funds, or start building a portfolio.
Data updated on 2026-09-18